Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), William L. Dahut(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Howard L. Parnes(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), Matteo Vergati(National Institutes of Health), Diane J. Poole(National Institutes of Health), Myrna Rauckhorst(National Institutes of Health), Kwong Y. Tsang(Center for Biologics Evaluation and Research), Mahsa Mohebtash(National Institutes of Health)
Cited by 327
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817